Home600664 • SHA
add
Harbin Pharmaceutical Group Co., Ltd.
Previous close
¥3.73
Day range
¥3.65 - ¥3.78
Year range
¥2.41 - ¥4.26
Market cap
9.29B CNY
Avg Volume
48.78M
P/E ratio
15.63
Dividend yield
-
Primary exchange
SHA
Market news
Financials
Income Statement
Revenue
Net income
(CNY) | Sep 2024info | Y/Y change |
---|---|---|
Revenue | 4.11B | 8.54% |
Operating expense | 833.10M | 0.85% |
Net income | 164.90M | 52.98% |
Net profit margin | 4.01 | 41.20% |
Earnings per share | — | — |
EBITDA | 318.87M | 26.26% |
Effective tax rate | 23.46% | — |
Balance Sheet
Total assets
Total liabilities
(CNY) | Sep 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 3.13B | 13.03% |
Total assets | 14.27B | 2.51% |
Total liabilities | 8.32B | -3.45% |
Total equity | 5.95B | — |
Shares outstanding | 2.52B | — |
Price to book | 1.80 | — |
Return on assets | 4.51% | — |
Return on capital | 8.25% | — |
Cash Flow
Net change in cash
(CNY) | Sep 2024info | Y/Y change |
---|---|---|
Net income | 164.90M | 52.98% |
Cash from operations | 105.03M | -61.67% |
Cash from investing | -35.33M | 74.29% |
Cash from financing | -173.45M | -5,358.43% |
Net change in cash | -104.01M | -174.49% |
Free cash flow | -77.99M | 22.01% |
About
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate.
The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
Founded
1988
Website
Employees
9,853